131 related articles for article (PubMed ID: 37846412)
1. Extraordinarily high serum CA 19-9 in setting of pancreatic necrosis and underlying pancreatic adenocarcinoma: a case report.
McConnell A; Stoneman T; Hewlett S
J Surg Case Rep; 2023 Oct; 2023(10):rjad550. PubMed ID: 37846412
[TBL] [Abstract][Full Text] [Related]
2. A Case of Choledocholithiasis and Obstructive Jaundice With a Very High Serum Carbohydrate Antigen 19-9 (CA 19-9) Level: A Case Report and Review of Literature.
Ghallab M; Abosheaishaa H; Gupta I; Abdelmoteleb S; Stern R
Cureus; 2022 Dec; 14(12):e32447. PubMed ID: 36644102
[TBL] [Abstract][Full Text] [Related]
3. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
[TBL] [Abstract][Full Text] [Related]
4. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.
Ballehaninna UK; Chamberlain RS
J Gastrointest Oncol; 2012 Jun; 3(2):105-19. PubMed ID: 22811878
[TBL] [Abstract][Full Text] [Related]
5. Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review.
Ballehaninna UK; Chamberlain RS
Indian J Surg Oncol; 2011 Jun; 2(2):88-100. PubMed ID: 22693400
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune Pancreatitis Masquerading as Pancreatic Cancer: A Case Report and Literature Review.
Agarwal KK; Jassal R; Browne A; Hossain M; Akhtar R
Cureus; 2022 Feb; 14(2):e21900. PubMed ID: 35265424
[TBL] [Abstract][Full Text] [Related]
7. Neopterin serum levels in pancreatic adenocarcinoma.
Manes G; Spada OA; Rabitti PG; Feola B; Misso S; Minerva A; Uomo G
Int J Pancreatol; 1999 Feb; 25(1):31-7. PubMed ID: 10211419
[TBL] [Abstract][Full Text] [Related]
8. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice.
Duraker N; Hot S; Polat Y; Höbek A; Gençler N; Urhan N
J Surg Oncol; 2007 Feb; 95(2):142-7. PubMed ID: 17262731
[TBL] [Abstract][Full Text] [Related]
9. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
[TBL] [Abstract][Full Text] [Related]
10. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers.
Koopmann J; Buckhaults P; Brown DA; Zahurak ML; Sato N; Fukushima N; Sokoll LJ; Chan DW; Yeo CJ; Hruban RH; Breit SN; Kinzler KW; Vogelstein B; Goggins M
Clin Cancer Res; 2004 Apr; 10(7):2386-92. PubMed ID: 15073115
[TBL] [Abstract][Full Text] [Related]
11. Is CA242 really a new tumour marker for pancreatic adenocarcinoma?
Plebani M; Basso D; Navaglia F; D'Angeli F; Panozzo MP; Del Giudice G; Battistel M; Meggiato T; Del Favero G
Oncology; 1995; 52(1):19-23. PubMed ID: 7800337
[TBL] [Abstract][Full Text] [Related]
12. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis.
Malesci A; Tommasini MA; Bonato C; Bocchia P; Bersani M; Zerbi A; Beretta E; Di Carlo V
Gastroenterology; 1987 Jan; 92(1):60-7. PubMed ID: 3465666
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
[TBL] [Abstract][Full Text] [Related]
14. DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease.
Mahvi DM; Seigler HF; Meyers WC; Kalthoff H; Schmiegel WH; Metzgar RS
Pancreas; 1988; 3(4):488-93. PubMed ID: 3174610
[TBL] [Abstract][Full Text] [Related]
15. Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19-9.
Haglund C; Kuusela P; Jalanko H; Roberts PJ
Int J Cancer; 1987 Apr; 39(4):477-81. PubMed ID: 3470260
[TBL] [Abstract][Full Text] [Related]
16. CA 19-9: Biochemical and Clinical Aspects.
Scarà S; Bottoni P; Scatena R
Adv Exp Med Biol; 2015; 867():247-60. PubMed ID: 26530370
[TBL] [Abstract][Full Text] [Related]
17. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
[TBL] [Abstract][Full Text] [Related]
18. Clinical Interpretation of Elevated CA 19-9 Levels in Obstructive Jaundice Following Benign and Malignant Pancreatobiliary Disease.
Kim MS; Jeon TJ; Park JY; Choi J; Shin WC; Park SE; Seo JY; Kim YM
Korean J Gastroenterol; 2017 Aug; 70(2):96-102. PubMed ID: 28830135
[TBL] [Abstract][Full Text] [Related]
19. A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1992; 12(6B):2309-14. PubMed ID: 1295478
[TBL] [Abstract][Full Text] [Related]
20. Extraordinarily elevated serum levels of CA 19-9 and rapid decrease after successful therapy: a case report and review of literature.
Korkmaz M; Ünal H; Selçuk H; Yilmaz U
Turk J Gastroenterol; 2010 Dec; 21(4):461-3. PubMed ID: 21332006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
